Patents by Inventor Luc Mercken

Luc Mercken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of screening for gamma-secretase activity
    Patent number: 7892778
    Abstract: The present invention relates to an improved process for determining ?-secretase activity and for detecting ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase. In particular, the present invention relates to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase. Another embodiment of the present invention relates to processes for the identification of substances which can inhibit the activity of ?-secretase, or a ?-secretase-like proteinase.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: February 22, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Edmund Hoppe, Gisela Peraus, Jonathan Rothblatt, Ekkehard Leberer, Luc Mercken, Sylvie Dreisler
  • FEBP1 protein vector host cells and method for making FEBP1 protein
    Patent number: 6942982
    Abstract: The present invention relates to novel compounds and their pharmaceutical or diagnostic use, or use as a pharmacological target. More particularly, the present invention describes the identification of partners of the FE65 protein and the use of these partners, or of any compound which is capable of modulating, at least partially, their interaction with FE65, for regulating the activity of FE65, and in particular the phenomenon of intracellular transport or of endocytosis of the APP.
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: September 13, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Isabelle Maury, Luc Mercken, Alain Fournier
  • A-beta-peptide screening
    Publication number: 20050032150
    Abstract: The present invention relates to an improved process for determining ?-secretase activity and for detecting ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase; particular embodiments of the process relate on the one hand to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase, and on the other hand to processes for the identification of substances which can inhibit the activity of a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase.
    Type: Application
    Filed: May 19, 2004
    Publication date: February 10, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Edmund Hoppe, Gisela Peraus, Jonathan Rothblatt, Ekkehard Leberer, Luc Mercken, Sylvie Dreisler
  • Inhibitors of Src kinase for use in alzheimer's disease
    Publication number: 20040176313
    Abstract: The present invention relates to the identification of inhibitors of Src kinase, assays and methods useful for such identification and the use of Src inhibitors for the preparation of pharmaceuticals for the treatment of Alzheimer's disease.
    Type: Application
    Filed: October 22, 2003
    Publication date: September 9, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Luc Mercken, Nicola Zambrano, Tommaso Russo
  • FEBP1 protein vector host cells and method for making FEBP1 protein
    Publication number: 20040166109
    Abstract: The present invention relates to novel compounds and their pharmaceutical or diagnostic use, or use as a pharmacological target. More particularly, the present invention describes the identification of partners of the FE65 protein and the use of these partners, or of any compound which is capable of modulating, at least partially, their interaction with FE65, for regulating the activity of FE65, and in particular the phenomenon of intracellular transport or of endocytosis of the APP.
    Type: Application
    Filed: December 3, 2003
    Publication date: August 26, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Isabelle Maury, Luc Mercken, Alain Fournier
  • FEBP1 Protein: vector, host cells and method for making FEBP1 protein
    Patent number: 6696273
    Abstract: The present invention relates to novel compounds and their pharmaceutical or diagnostic use, or use as a pharmacological target. More particularly, the present invention describes the identification of partners of the FE65 protein and the use of these partners, or of any compound which is capable of modulating, at least partially, their interaction with FE65, for regulating the activity of FE65, and in particular the phenomenon of intracellular transport or of endocytosis of the APP.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: February 24, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Isabelle Maury, Luc Mercken, Alain Fournier
  • Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the &bgr;-amyloid peptide
    Patent number: 6653088
    Abstract: Provided herein are novel peptide and nucleotide sequences, their pharmaceutical use, as well as novel polypeptides capable of inhibiting at least partially the interaction between presenilin 1 or presenilin 2 and the &bgr;-amyloid peptide precursor or a &bgr;-amyloid peptide; also provided are in vitro tests and methods for detecting molecules and in particular, molecules capable of inhibiting said interaction.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: November 25, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Christian Czech, Luc Mercken, Laurent Pradier, Soline Reboul-Becquart
  • Partners of the PTB1 domain of FE65, preparation and uses
    Publication number: 20020061553
    Abstract: The present invention relates to novel compounds and their pharmaceutical or diagnostic use, or use as a pharmacological target. More particularly, the present invention describes the identification of partners of the FE65 protein and the use of these partners, or of any compound which is capable of modulating, at least partially, their interaction with FE65, for regulating the activity of FE65, and in particular the phenomenon of intracellular transport or of endocytosis of the APP.
    Type: Application
    Filed: February 9, 2001
    Publication date: May 23, 2002
    Inventors: Isabelle Maury, Luc Mercken, Alain Fournier